Founder of the Center for Carcinoid and Neuroendocrine Tumors at Mount Sinai
Founder of the Carcinoid Cancer Foundation
BA Oberlin College, MD University of Cincinnati (1951 Alpha Omega Alpha); internal medicine residency, gastroenterology Research, fellowships and NIH traineeship at Mount Sinai.
In 1972, awarded the honor of Grand Commander of the Humane Order of African Redemption (Monrovia), and in 2002 the Catherine Margaret Pasmantier Award of the New York Cancer Society and the Fund for Blood and Cancer Research. In October 2009 honored as the first recipient of the annual Lifetime Achievement Award of The North American Neuroendocrine Tumor Society (NANETS) for a lifetime of work and accomplishment with carcinoid/NETS. He has been the Principal Investigator of the longest continuously IRB-approved research project at Mount Sinai School of Medicine (1958-2011) and is an advisor to the Board of Directors of NANETS, and a member of the Editorial Board of the Journal of Oncopathology. In 2012 he received the Distinguished Partner of Hope award of the Abramson Cancer Center of Penn Medicine Focus on Neuroendocrine Tumors.
Perhaps most notable of the scores of carcinoid NETs publications by Dr Warner . are: the first description of carcinoid syndrome resulting from bronchial carcinoid (1958); hyperserotoninemia in IBS (1963);the first report of intrahepatic artery injection of Y-90 microspheres for treatment of carcinoid liver metastases-5 cases-(1968), the first large series reported of carcinoid syndrome patients treated by hepatic artery chemoembolus injection (HACE) (1985)and in June 2008 he coauthored a multiinstitutional report on the outcome of Yttrium-90 radioembolus treatment of neuroendocrine tumor metastases of the liver in 148 cases. He continues to be actively involved in teaching, conducting a clinical consultation practice, and research.